Loading patent…
AssigneeGenentech, Inc.
InventorsMatthew KALO, Abigail Friederike Joyce PYNN, Lindsey Marie SILVA, Anjali SRIVASTAVA, Jayashree SUBRAMANIAN, Siddharth SUKUMARAN, Amy YOUNG, Tomasz BAGINSKI, Tracy Jane BENTLEY, Jeremy BESMER, Sherrie Patrice CURTIS, Peter William DAY
Estimating the term…
The invention relates to IL-22 Fc fusion proteins, composition comprising the same, methods of making and/or purifying the same, methods of selecting batches of IL-22 Fc fusion proteins or compositions thereof, and methods of using the composition for the treatment of diseases (e.g., IBD).
A composition comprising an interleukin-22 (IL-22) Fc fusion protein, wherein the IL-22 Fc fusion protein binds to human IL-22 receptor and comprises a glycosylated IL-22 polypeptide linked to an antibody Fc region by a linker, wherein the glycosylated IL-22 polypeptide is sialylated, wherein the composition has an average sialic acid content in the range of 8 to 12 moles of sialic acid per mole of the IL-22 Fc fusion protein, and wherein the composition is a liquid composition.
(canceled)
4-6. (canceled)
8-12. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
32-36. (canceled)
38-41. (canceled)
43-49. (canceled)
52-85. (canceled)
A method of selecting a batch comprising an IL-22 Fc fusion protein for release, the method comprising the following steps:
87-91. (canceled)
A method for controlling sialic acid content of a composition comprising an IL-22 Fc fusion protein, the IL-22 Fc fusion protein comprising a glycosylated IL-22 polypeptide linked by a linker to an antibody Fc region, the method comprising:
93-103. (canceled)
Dependencies are inferred from the claim text.